Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
- Conditions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 51
- Registration Number
- NCT00305812
- Locations
- 🇨🇦
Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada
🇨🇦Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
🇨🇦Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00294632
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Kenneth Ain
- Target Recruit Count
- 25
- Registration Number
- NCT00287287
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00267059
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00253344
- Locations
- 🇺🇸
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 97
- Registration Number
- NCT00238238
- Locations
- 🇺🇸
Menorah Medical Center, Overland Park, Kansas, United States
🇺🇸Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Memorial Hospital, Carthage, Illinois, United States
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00227591
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT00179673
- Locations
- 🇺🇸
Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00179660
- Locations
- 🇺🇸
UC David Cancer Center, Sacramento, California, United States
🇺🇸New York Medical Center, MBCCOP, Bronx, New York, United States
🇺🇸Sylvester Cancer CenterUniversity Of Miami, Miami, Florida, United States
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 1913
- Registration Number
- NCT00179647
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Cedar Sinai Medical CenterDept of Medicine, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.